About Andrew Thomson
Andrew Thomson is a president and director at Modulate Bio.
Andrew Thomson first appears on SEC filings in 2024.
Experience
This experience comes from Andrew Thomson's profile and from SEC filings. For roles taken from filings, the years are when the filings name Andrew Thomson in the role, so the role may have started earlier or lasted longer.
IP
Ipsen Current
Business Development Partner
2025 – Present
Modulate Bio Inc. Current
President and director
CEO + Co-founder (2023 – Present)
2023 – Present · Allston, MA
Develops medicines for people with neurological disorders, including essential tremor and epilepsy.
2V
2048 Ventures
Network Partner (Part-Time)
2024 – 2025
HS
Harvard Business School
Blavatnik Fellowship in Life Sciences Entrepreneurship
2022 – 2025
CA
Charles River Associates
Senior Associate
2017 – 2022
SP
Social Venture Partners
Project Team Lead for Fathers' Uplift
2018 – 2021
RA
RTI Innovation Advisors
Analyst (Part Time)
2018
ML
Morgan Tissue-Engineering Labs
Tissue Engineering Researcher
2016
LI
Labsphere, Inc.
Research Development Engineering Intern
2015
Key Colleagues at Startups
The people Andrew Thomson works with at each company, as listed on that company's latest Form D.
Modulate Bio Inc. · Form D/A, Apr 7, 2026
KH
Kevin Hodgetts
Promoter
DD
Dario Doller
Executive officer, director and promoter